Dapagliflozin for peritoneal dialysis patients with chronic heart failure in Japan: a multicenter, open-label, randomized controlled trial (jDAPA-PD)

未提供0 个研究点目标入组 40 人开始时间: 2024年6月17日最近更新: 2025年6月17日

试验速览

暂无简介。

•Patients who provide written consent based on their own free will to participate in this study.
•Patients who are 18 years of age or older
•Patients who are undergoing peritoneal dialysis for the treatment of end-stage kidney disease for more than 3 months
•Patients whose peritoneal dialysis regimen is stable for at least 4 weeks
•Patients who are diagnosed with chronic heart failure and receiving standard treatment

•Patients who are participating in other clinical studies
•Patients who are pregnant or breast feeding
•Patients who have received SGLT2 inhibitors within 4 weeks
•Patients who have received hemodialysis within 4 weeks
•Patients who are treated for peritonitis within 4 weeks
•Patients with a daily urine volume of less than 500 mL
•Patients who have difficulty with infusion and drainage of peritoneal dialysis dialysate
•Patients who are considering discontinuation of peritoneal dialysis within 8 weeks after enrollment.
•Patients who have difficulty performing bioelectrical impedance analysis tests (pacemakers, and limb defects)
•Patients who are allergic to dapagliflozin
•Patients who are considered inappropriate to participate by investigators

Change in extracellular water from baseline to week 24

发起方

未提供